[1] Willebrords J, Pereira IV, Maes M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59: 106-125.
[2] Karim MF, Al-Mahtab M, Rahman S, et al. Non-alcoholic fatty liver disease (nafld)-a review[J]. Mymensingh Med J, 2015, 24(4): 873-880.
[3] Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease [J]. Atherosclerosis, 2015, 239(1): 192-202.
[4] Patel K, Gadewar M, Tahilyani V, et al. A review on pharmacological and analytical aspects of diosmetin: A concise report[J]. Chin J Integr Med, 2013, 19(10):792-800.
[5] Federico A, Zulli C, de Sio I, et al. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(45): 16841-16857.
[6] Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease[J]. Dig Liver Dis, 2015, 47(1): 4-11.
[7] Rios JL, Francini F, Schinella GR. Natural products for the treatment of type 2 diabetes mellitus[J]. Planta Med, 2015, 81(12-13): 975-994.
[8] Xu JY, Zhang L, Li ZP, et al. Natural products on nonalcoholic fatty liver disease[J]. Curr Drug Targets, 2015, 16(12): 1347-1355.
[9] Jeon BT, Heo RW, Shin HJ, et al. Attenuation by a vigna nakashimae extract of nonalcoholic fatty liver disease in high-fat diet-fed mice[J]. Biosci Biotechnol Biochem, 2014, 78(3): 482-489.
[10] de Oliveira PR, da Costa CA, de Bem GF, et al. Euterpe oleracea mart.-derived polyphenols protect mice from diet-induced obesity and fatty liver by regulating hepatic lipogenesis and cholesterol excretion[J]. PloS One, 2015, 10(12): e0143721.
[11]Michael HN, Salib JY, Eskander EF. Bioactivity of diosmetin glycosides isolated from the epicarp of date fruits, phoenix dactylifera, on the biochemical profile of alloxan diabetic male rats[J]. Phytother Res : PTR, 2013, 27(5): 699-704.
[12]Kang H, Koppula S. Houttuynia cordata alleviates high-fat diet-induced non-alcoholic fatty liver in experimental rats[J]. Pharm Biol, 2015, 53(3): 414-422.
[13]Xiao J, Ho CT, Liong EC, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through tgf/smad, pi3 k/akt/foxo1, and nf-kappa b pathways[J]. Eur J Nutr, 2014, 53(1): 187-199.
[14]Shen Z, Shao J, Dai J, et al. Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress[J]. Toxicol Rep, 2015, 3: 78-86.
[15]Yang Y, Gong XB, Huang LG, et al. Diosmetin exerts anti-oxidative, anti-inflammatory and anti-apoptotic effects to protect against endotoxin-induced acute hepatic failure in mice[J]. Oncotarget, 2017, 8(19): 30723-30733.
[16]Zou X, Yan C, Shi Y, et al. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin[J]. Antioxid Redox Signal, 2014, 21(11): 1557-1570.
[17]Chang CJ, Liou SS, Tzeng TF, et al. The ethanol extract of zingiber zerumbet smith attenuates non-alcoholic fatty liver disease in hamsters fed on high-fat diet[J]. Food Chem Toxicol, 2014, 65: 33-42.
[18]Lin J, Zhang Y, Wang X, et al. Lycium ruthenicum extract alleviates high-fat diet-induced nonalcoholic fatty liver disease via enhancing the ampk signaling pathway[J]. Mol Med Rep, 2015, 12(3): 3835-3840.
[19]Yang K, Li WF, Yu JF, et al. Diosmetin protects against ischemia/reperfusion-induced acute kidney injury in mice[J]. J Surg Res, 2017, 214: 69-78.
[20]Yu G, Wan R, Yin G, et al. Diosmetin ameliorates the severity of cerulein-induced acute pancreatitis in mice by inhibiting the activation of the nuclear factor-kappab[J]. Int J Clin Exp Pathol, 2014, 7(5): 2133-2142.
[21]Liu Q, Ci X, Wen Z, et al. Diosmetin alleviates lipopolysaccharide-induced acute lung injury through activating the nrf2 pathway and inhibiting the nlrp3 inflammasome[J]. Biomol Ther, 2018, 26(2): 157-166. |